Results 51 to 60 of about 24,853 (244)

Off‐Label Use of Topical Ruxolitinib in Dermatology: A Systematic Literature Review and Current Perspectives

Experimental Dermatology
JAK inhibitors are used to treat various inflammatory skin diseases. However, systemic formulations are associated with an increased risk of major adverse events.
M. Spadafora, Serena Morsia, V. Di Lernia, S. Kaleci, G. Pellacani, C. Longo   +5 more
semanticscholar   +1 more source

What Makes an “Ideal” Cell Line for Recombinant Adeno‐Associated Virus Production?

Biotechnology and Bioengineering, EarlyView.
Several host cell types have been used to produce rAAVs to date. Cell line‐specific traits that are beneficial in the context of rAAV manufacturing are reviewed here, with the goal of developing a consensus on the ‘ideal’ characteristics that an rAAV production host should possess (created with Biorender.com).
James Conheady, Nicholas Donohue, Alexandra Bogdanovic, Sharon Davin, Brian Glennon, Niall Barron, C. Mark Smales   +6 more
wiley   +1 more source

Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety

Journal of Hematology & Oncology, 2023
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, anemia, extramedullary hematopoiesis, and splenomegaly.
S. Verstovsek, R. Mesa, R. Livingston, Wilson Hu, J. Mascarenhas   +4 more
semanticscholar   +1 more source

Fecal Microbiota Transplantation and Microbiota‐Based Therapeutics in Allogeneic Hematopoietic Stem Cell Transplantation: Current Evidence and Future Directions

Clinical Pharmacology &Therapeutics, EarlyView.
The intestinal microbiome is a key regulator of immune homeostasis, metabolism, and epithelial barrier integrity. In patients with malignant hematological diseases, particularly those undergoing hematopoietic stem cell transplantation, microbiome perturbations by reduced diversity, pathobiont expansion, and loss of beneficial metabolites are common as ...
Bálint Gergely Szabó, Dorina Korózs, Michal Bator, Krisztina Jeszenszky, Viktor Lakatos, László Gopcsa, Péter Reményi, János Sinkó   +7 more
wiley   +1 more source

Type II mode of JAK2 inhibition and destabilization are potential therapeutic approaches against the ruxolitinib resistance driven myeloproliferative neoplasms

Frontiers in Oncology
BackgroundRuxolitinib has been approved by the US FDA for the treatment of myeloproliferative neoplasms such as polycythemia vera and primary myelofibrosis.
Sivahari P. Gorantla, Sivahari P. Gorantla, Gerin Prince, Jasmin Osius, Dhurvas Chandrasekaran Dinesh, Vijay Boddu, Justus Duyster, Nikolas von Bubnoff   +7 more
doaj   +1 more source

Neoadjuvant Cemiplimab for Resectable Locoregionally Advanced Cutaneous Squamous Cell Carcinoma: A Case Series

Head &Neck, EarlyView.
ABSTRACT Introduction A Phase II trial demonstrated that neoadjuvant cemiplimab was associated with pathologic complete response (pCR) in 51% of patients with locoregionally advanced cutaneous squamous cell carcinoma (cuSCC). We evaluated real‐world radiographic and pathologic responses to neoadjuvant cemiplimab and assessed radiologic–pathologic ...
Whitney Jin, Ryan K. Rigsby, Kim Ely, Austin Hoke, Robert Sinard, Kyle Mannion, Jill Gilbert, Lindsay Mundy, Alexander Langerman, Sarah Rohde, Barbara Murphy, Eben Rosenthal, Mitra Mehrad, Michael C. Topf, Jennifer H. Choe   +14 more
wiley   +1 more source

Prevention of Irreversible Autoimmune Endocrinopathies in APECED with Ruxolitinib

Journal of Human Immunity
Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED/APS-1) is a monogenic disorder of failed central tolerance caused by deleterious variants in the autoimmune regulator (AIRE) gene. Interferon-γ-driven inflammation in APECED underlies
Joseph Pechacek, Taura Webb, Lucas dos Santos Dias, Rachel Wu, Heather Moorman, Princess Barber, Lindsey Rosen, Benjamin Colton, Herodes Guzman, Maria Sacta, Shana McCormack, Aaron Bennett, Kathleen Loomes, Neil Romberg, Niamh McGrath, Steven Holland, Theo Heller, Karen Winer, Stefania Pittaluga, Michail Lionakis   +19 more
doaj   +1 more source

PHASE I and Randomized Phase II STUDY OF RUXOLITINIB WITH FRONT-LINE NEOADJUVANT THERAPY IN ADVANCED OVARIAN CANCER: An NRG Oncology Group Study

Journal of Clinical Oncology
PURPOSE The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance.
Charles N. Landen, Ronald J Buckanovich, M. Sill, R. Mannel, Joan L. Walker, P. DiSilvestro, Cara Mathews, D. Mutch, Marcia L. Hernandez, Lainie P. Martin, Erin Bishop, S. Gill, Mary E. Gordinier, Robert A. Burger, C. Aghajanian, Joyce F. Liu, K. Moore, M. Bookman   +17 more
semanticscholar   +1 more source

Topical ruxolitinib: A new treatment for vitiligo

Journal of the European Academy of Dermatology and Venereology, 2023
Vitiligo is a chronic autoimmune skin disorder whose diagnosis is often psychologically upsetting. The efficacy of the available therapies, including topical corticosteroids and topical calcineurin inhibitors, has historically been limited and the ...
G. Tavoletti, G. Avallone, C. Conforti, G. Roccuzzo, C. Maronese, M. A. Mattioli, P. Quaglino, I. Zalaudek, A. Marzano, S. Ribero, S. Alberti-Violetti   +10 more
semanticscholar   +1 more source

Ruxolitinib mediated paradoxical JAK2 hyperphosphorylation is due to the protection of activation loop tyrosines from phosphatases

Leukemia
Myelofibrosis (MF) in 50% of cases is driven by an activating JAK2 mutation, mostly V617F. Ruxolinitib is approved for the treatment of MF. Responses to ruxolitinib in MF are of limited duration.
S. P. Gorantla, Lorenz Oelschläger, Gerin Prince, Jasmin Osius, Suresh Babu Kolluri, Y. Maluje, A. Fähnrich, Nancy Ernst, Alanis Barbosa Gulde, R. Ludwig, T. Gemoll, Stephanie Fliedner, W. Walter, Torsten Haferlach, N. Gebauer, H. Busch, J. Duyster, N. von Bubnoff   +17 more
semanticscholar   +1 more source